Pfizer Inc Q4 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : I guess first question on COVID and to sort of piggyback on what Geoff was asking. I mean from your slides and comments, you're clearly expecting a sort of stable vaccine utilization rate when, in the last 12 months, we've seen this number decline on a backdrop of a virus that is evolving to less clinically severe variants. And so what underpins your confidence in these longer-term assumptions? And then also in terms of your COVID '23 guidance, you mentioned you'd guided to a sufficient range of variations in infection rates, et cetera. I was just wondering how much an allowance you've made for the potential timing or reduction in contractual orders as is the current situation with the Brussels negotiation? And then maybe just a quick one on the pipeline DMD. This feels noticeably in the background versus other assets at a similar stage. Just could you update us on your level of enthusiasm and commitment to this program, especially in light of the potential competitor approval in May of this year? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 31, 2023 / 3:00PM, PFE.N - Q4 2022 Pfizer Inc Earnings Call

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : A couple of questions on vaccines, please. Firstly, on RSV, can you confirm you're on track to provide that second season of data ahead of approval and reimbursement discussions in May-June for the older adult vaccine? And can you confirm whether you've now filed your maternal RSV vaccine with the regulator? If not, are you waiting for the approval in the older adult setting first? And then just on the flu/COVID combo, if we assume you have positive flu Phase 3 data in the second half of the year, positive Phase 1 combo data in the first half, would you expect to move the combo into Phase 3? Or is there a possibility you will not need a full Phase 3 combo study to proceed to filing an approval?